Pharmacogenomics and the Future of Drug Therapy

Pediatric Clinics of North America

Volumn 53, Issue 4, 2006, Pages 591-619

  Hines, Ronald N ^a,b   McCarver, D Gail ^a,b  

^a Pharmacogenetics and Teratology   (United States)

^b CHILDREN S HOSPITAL OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBENZOIC ACID; ACETYLISONIAZID; ATRELEUTON; AZATHIOPRINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CISAPRIDE; CORTICOSTEROID; COUMARIN; DEBRISOQUINE; FLUOXETINE; HYDRALAZINE; ISONIAZID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MERCAPTOPURINE; MONTELUKAST; NEDOCROMIL; PRANLUKAST; PROTEIN; PROTEIN ADRB2; PROTEIN CYP2D6; SULFADIMIDINE; SULFANILAMIDE; THEOPHYLLINE; THIORIDAZINE; TIOGUANINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN K GROUP; WARFARIN; ZAFIRLUKAST; ZILEUTON;

ASTHMA; CHILDHOOD CANCER; CLINICAL TRIAL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG INACTIVATION; DRUG METABOLISM; DRUG RESPONSE; ECONOMIC ASPECT; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MEDICAL ETHICS; NONHUMAN; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; PHARMACOGENOMICS; REVIEW; THROMBOEMBOLISM; TUBERCULOSIS;

ADRENAL CORTEX HORMONES; ASTHMA; DRUG THERAPY; FORECASTING; HUMANS; LEUKOTRIENE ANTAGONISTS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA-2; SIGNAL TRANSDUCTION;

EID: 33746189515     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2006.05.008     Document Type: Review

References (100)

1. Spear B.B., Heath-Chiozzi M., and Huff J. Clinical application of pharmacogenetics. Trends Mol Med 7 5 (2001) 201-204
2. Lazarou J., Pomeranz B.H., and Corey P.N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. J Am Med Assoc 279 15 (1998) 1200-1205
3. Meletis J., and Konstantopoulos K. Favism-from the avoid fava beans of Pythagoras to the present. Haema 7 1 (2004) 17-21
4. Bottini E., Bottini F.G., Borgiani P., et al. Association between ACP1 and favism: a possible biochemical mechanism. Blood 89 7 (1997) 2613-2615
5. Porter I.H., Boyer S.N., Watson-Williams E.J., et al. Variation of glucose-6-phosphate dehydrogenase in different populations. Lancet 42 (1964) 895-899
6. Garrod A.E., and Oxon M.D. The incidence of alkaptonuria: a study in chemical individuality. Lancet 2 (1902) 1616-1620
7. Snyder L.H. Studies in human inheritance. IX. The inheritance of taste deficiency in man. Ohio J Sci 32 (1932) 436-438
8. Motulsky A.G. Drug reactions, enzymes and biochemical genetics. J Am Med Assoc 165 7 (1957) 835-837
9. Vogel F. Moderne probleme der humangenetik. Ergeb Inn Med Kinderheilkd 12 (1959) 52-125
10. Selikoff I.J., Robitzek E.H., and Ornstein G.G. Treatment of pulmonary tuberculosis with hydrazide derivatives of isonicotinic acid. J Am Med Assoc 150 10 (1952) 973-980
11. Evans D.A., Manley K.A., and McKusick V.A. Genetic control of isoniazid metabolism in man. BMJ 5197 (1960) 485-491
12. Evans D.A.P., and White T.A. Human acetylation polymorphism. J Lab Clin Med 63 3 (1964) 394-403
13. Blum M., Demierre A., Grant D.M., et al. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci U S A 885 (1991) 237-241
14. Hein D.W. N-acetyltransferase 2 polymorphism: effects of carcinogen and haplotype on urinary bladder risk. Oncogene 25 11 (2006) 1649-1658
15. Lacroix D., Sonnier M., Moncion A., et al. Expression of CYP3A in the human liver. Evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 247 (1997) 625-634
16. Stevens J.C., Hines R.N., Gu C., et al. Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther 307 2 (2003) 573-582
17. Tréluyer J.M., Rey E., Sonnier M., et al. Evidence of impaired cisapride metabolism in neonates. Br J Clin Pharmacol 52 4 (2001) 419-425
18. Pearce R.E., Gotschall R.R., Kearns G.L., et al. Cytochrome P450 involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual CYP3A isoforms. Drug Metab Dispos 29 12 (2001) 1548-1554
19. Koukouritaki S.B., Simpson P., Yeung C.K., et al. Human hepatic flavin-containing monooxygenase 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr Res 51 2 (2002) 236-243
20. Mayatepek E., and Kohlmüeller D. Transient trimethylaminuria in childhood. Acta Paediatr 87 11 (1998) 1205-1207
21. Tateishi T., Asoh M., Yamaguchi A., et al. Developmental changes in urinary elimination of theophylline and its metabolites in pediatric patients. Pediatr Res 45 1 (1999) 66-70
22. Sonnier M., and Cresteil T. Delayed ontogenesis of CYP1A2 in the human liver. Eur J Biochem 251 3 (1998) 893-898
23. Leeder J.S. Pharmacogenetics and pharmacogenomics. Pediatr Clin North Am 48 3 (2001) 765-781
24. Wilkinson G.R. Drug metabolism and variability among patients in drug response. N Engl J Med 352 21 (2005) 2211-2221
25. Bomgaars L., and McLeod H.L. Pharmacogenetics and pediatric cancer. Cancer J 11 4 (2005) 314-323
26. Mahgoub A., Dring L.G., Idle J.R., et al. Polymorphic hydroxylation of debrisoquine in man. Lancet 2 8038 (1977) 584-586
27. Gonzalez F.J., Skoda R.C., Kimura S., et al. Characterization of the common genetic defect in humans deficient in debrisoquin metabolism. Nature 331 6155 (1988) 442-446
28. Weinshilboum R.M., and Sladek S.L. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32 5 (1980) 651-662
29. McLeod H.L., and Siva C. The thiopurine S-methyltransferase gene locus-implications for clinical pharmacogenomics. Pharmacogenomics 3 1 (2002) 89-98
30. Spire-Vayron de la Moureyre C., Debuysere H., Mastain B., et al. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br J Pharmacol 125 4 (1998) 879-887
31. Yan L., Zhang S., Eiff B., et al. Thiopurine methyltransferase polymorphic tandem repeat: genotype-phenotype correlation analysis. Clin Pharmacol Ther 68 2 (2000) 210-219
32. Black A.J., McLeod H.L., Capell H.A., et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 129 9 (1998) 716-718
33. Ishioka S., Hiyama K., Sato H., et al. Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese. Intern Med 38 12 (1999) 944-947
34. McLeod H.L., Coulthard S., Thomas A.E., et al. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br J Haematol 105 3 (1999) 696-700
35. Relling M.V., Hancock M.L., Rivera G.K., et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 91 23 (1999) 2001-2008
36. Dervieux T., Medard Y., Baudouin V., et al. Thiopurine methyltransferase activity and its relationship to the occurrence of rejection episodes in paediatric renal transplant recipients treated with azathioprine. Br J Clin Pharmacol 48 6 (1999) 793-800
37. Tavadia S.M., Mydlarski P.R., Reis M.D., et al. Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J Am Acad Dermatol 42 4 (2000) 628-632
38. Andrew M., Marzinotto V., Brooker L.A., et al. Oral anticoagulation therapy in pediatric patients: a prospective study. Thromb Haemostas 71 3 (1994) 265-269
39. Kamali F., Khan T.I., King B.P., et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 75 3 (2004) 204-212
40. Rettie A.E., Korzekwa K.R., Kunze K.L., et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 5 1 (1992) 54-59
41. Peyvandi F., Spreafico M., Siboni S.M., et al. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin Pharmacol Ther 75 3 (2004) 198-203
42. Aithal G.P., Day C.P., Kesteven P.J.L., et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353 9154 (1999) 717-719
43. Taube J., Halsall D., and Baglin T. Influence of cytochrome P450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96 5 (2000) 1816-1819
44. Veenstra D.L., Blough D.K., Higashi M.K., et al. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin Pharmacol Ther 77 5 (2005) 353-364
45. Higashi M.K., Veenstra D.L., Kondo L.M., et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. J Am Med Assoc 287 13 (2002) 1690-1698
46. Rost S., Fregin A., Ivaskevicius V., et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427 6974 (2004) 537-541
47. Li T., Chang C.Y., Jin D.Y., et al. Identification of the gene for vitamin K epoxide reductase. Nature 427 6974 (2004) 541-544
48. D'Andrea G., D'Ambrosio R.L., Di Perna P., et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105 2 (2005) 645-649
49. Rieder M.J., Reiner A.P., Gage B.F., et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352 22 (2005) 2285-2293
50. Tantisira K.G., and Weiss S.T. The pharmacogenetics of asthma: an update. Curr Opin Mol Ther 7 3 (2005) 209-217
51. Drazen J.M., Silverman E.K., and Lee T.H. Heterogeneity of therapeutic responses in asthma. Br Med Bull 56 4 (2000) 1054-1070
52. Szefler S.J., Phillips B.R., Martinez F.D., et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 115 2 (2005) 233-242
53. Kennedy M.J., Carpenter J.M., Lozano R.A., et al. Impaired recovery of hypothalamic-pituitary-adrenal axis function and hypoglycemic seizures after high-dose inhaled corticosteroid therapy in a toddler. Ann Allergy Asthma Immunol 88 5 (2002) 523-526
54. Dunlop K.A., Carson D.J., and Shields M.D. Hypoglycemia due to adrenal suppression secondary to high-dose nebulized corticosteroid. Pediatr Pulmonol 34 1 (2002) 85-86
55. Lanes S.F., Garcia Rodriguez L.A., and Huerta C. Respiratory medications and risk of asthma death. Thorax 57 8 (2002) 683-686
56. Malmstrom K., Rodriguez-Gomez G., Guerra J., et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 130 6 (1999) 487-495
57. Wilk J.B., Djousse L., Arnett D.K., et al. Evidence for major genes influencing pulmonary function in the NHLBI family heart study. Genet Epidemiol 19 1 (2000) 81-94
58. Palmer L.J., Burton P.R., James A.L., et al. Familial aggregation and heritability of asthma-associated quantitative traits in a population-based sample of nuclear families. Eur J Hum Genet 8 11 (2000) 853-860
59. Murphy S, Bleecker ER, Boushey H, et al. Guidelines for the diagnosis and management of asthma. Highlights of the expert panel. NHLBI National Asthma Education and Prevention Program. Bethesda (MD): NIH Publications. 1997;2:1-153.
60. Leung D.Y., and Bloom J.W. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 111 1 (2003) 3-22
61. Szefler S.J., Martin R.J., King T.S., et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 109 3 (2002) 410-418
62. Tantisira K.G., Lake S., Silverman E.S., et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet 13 13 (2004) 1353-1359
63. Finotto S., Neurath M.F., Glickman J.N., et al. Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science 295 5553 (2002) 336-338
64. Tantisira K.G., Hwang E.S., Raby B.A., et al. TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci U S A 101 52 (2004) 18099-18104
65. Reihsaus E., Innis M., MacIntyre N., et al. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 8 3 (1993) 334-339
66. Martinez F.D., Graves P.E., Baldini M., et al. Association between genetic polymorphisms of the beta 2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 100 12 (1997) 3184-3188
67. Lima J.J., Thomason D.B., Hohamed M.H.N., et al. Impact of genetic polymorphism of the β2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther 65 5 (1999) 519-525
68. Israel E., Drazen J.M., Liggett S.B., et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 162 1 (2000) 75-80
69. Dishy V., Sofowora G.G., Xie H.G., et al. The effect of common polymorphisms of the β2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med 354 14 (2001) 1030-1035
70. Israel E., Chinchilli V.M., Ford J.G., et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 364 9444 (2004) 1505-1512
71. Tattersfield A.E., and Hall I.P. Are beta(2)-adrenoceptor polymorphisms important in asthma-an unraveling story. Lancet 364 9444 (2004) 1464-1466
72. Drysdale C.M., McGraw D.W., Stack C.B., et al. Complex promoter and coding region β2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A 97 19 (2000) 10483-10488
73. Silverman E.K., Kwiatkowski D.J., Sylvia J.S., et al. Family-based association analysis of beta(2)-adrenergic receptor polymorphisms in the childhood asthma management program. J Allergy Clin Immunol 112 5 (2003) 870-876
74. Small K.M., Brown K.M., Theiss C.T., et al. An Ile to Met polymorphism in the catalytic domain of adenylyl cyclase type 9 confers reduced beta2-adrenergic receptor stimulation. Pharmacogenetics 13 9 (2003) 535-541
75. Lam B.K., Owen Jr. W.F., Austen K.F., et al. The identification of a distinct export step following the biosynthesis of leukotriene C4 by human eosinophils. J Biol Chem 264 22 (1989) 12885-12889
76. Holgate S.T., Bradding P., and Sampson A.P. Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J Allergy Clin Immunol 98 1 (1996) 1-13
77. Busse W.W. Leukotrienes and inflammation. Am J Respir Crit Care Med 157 (1998) S210-S213
78. Lynch K.R., O'Neill G.P., Liu Q., et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399 6738 (1999) 789-793
79. Sarau H.M., Ames R.S., Chambers J., et al. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol 56 3 (1999) 657-663
80. Figueroa D.J., Breyer R.M., Defoe S.K., et al. Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes. Am J Respir Crit Care Med 163 1 (2001) 226-233
81. Zhu J., Qiu Y.S., Figueroa D.J., et al. Localization and upregulation of cysteinyl leukotriene-1 receptor in asthmatic bronchial mucosa. Am J Respir Cell Mol Biol 33 6 (2005) 531-540
82. In K.H., Asano K., Beier D., et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 99 5 (1997) 1130-1137
83. Drazen J.M., Yandava C.N., Dube L., et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to antiasthma treatment. Nat Genet 22 2 (1999) 168-170
84. Cowburn A.S., Sladek K., Soja J., et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 101 4 (1998) 834-846
85. Sanak M., Simon H.U., and Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 350 9091 (1997) 1599-1600
86. Sampson A.P., Siddiqui S., Buchanan D., et al. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 55 Suppl 2 (2000) S28-S31
87. Asano K., Shiomi T., Hasegawa N., et al. Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics 12 7 (2002) 565-570
88. Currie G.P., Lima J.J., Sylvester J.E., et al. Leukotriene C4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma. Br J Clin Pharmacol 56 4 (2003) 422-426
89. Kedda M.A., Shi J., Duffy D., et al. Characterization of two polymorphisms in the leukotriene C4 synthase gene in an Australian population of subjects with mild, moderate, and severe asthma. J Allergy Clin Immunol 113 5 (2004) 889-895
90. Lima J.J., Zhang S., Grant A., et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med 173 4 (2006) 379-385
91. Debouck C., and Metcalf B. The impact of genomics on drug discovery. Annu Rev Pharmacol Toxicol 40 (2000) 193-207
92. Roses A.D. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet 5 9 (2004) 645-656
93. Noble M.E., Endicott J.A., and Johnson L.N. Protein kinase inhibitors: insights into drug design from structure. Science 303 5665 (2004) 1800-1805
94. Danoff T.M., Campbell D.A., McCarthy L.C., et al. A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia. Pharmacogenomics J 4 1 (2004) 49-53
95. Xu C.F., Lewis K.F., Yeo A.J., et al. Identification of a pharmacogenetic effect by linkage disequilibrium mapping. Pharmacogenomics J 4 6 (2004) 374-378
96. Zineh I., Gerhard T., Aquilante C.L., et al. Availability of pharmacogenomics-based prescribing information in drug package inserts for currently approved drugs. Pharmacogenomics J 4 6 (2004) 354-358
97. Chou W.H., Yan F.X., de Leon J., et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol 20 2 (2000) 246-251
98. Lipton P., Afshar H., Bobrow M., et al. Pharmacogenetics. Ethical issues (2003), Nuffield Council on Bioethics, London p. 1-103
99. The troubled helix: Social and psychological implications of the new human genetics (1996), Cambridge University Press, Cambridge
100. Hughes D.A., Vilar F.J., Ward C.C., et al. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 14 6 (2004) 335-342